Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-875 plus metformin versus glimepiride plus metformin in type 2 diabetes
2011-001731-24Phase 3Terminated
- Sponsor
- Takeda
- Start
- Dec 2011
- Modality
- Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fasiglifam, glimepiride and metformin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Takeda. Primary endpoints: Change from baseline in HbA1c at Week 78 and Change from baseline in HbA1c at Week 104. Started Dec 2011; status: terminated.
02
Drugs
fasiglifamglimepiridemetformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2011-001731-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001731-24.